Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical's Subsidiary Astex Enters New Consortium for Drug Discovery Research at the University of Cambridge
Otsuka Pharmaceutical Co., Ltd. announces that its U.K. subsidiary Astex Pharmaceuticals has entered into a newly-formed consortium that will be hosted at the University of Cambridge.
(For detailed information please refer to the July 28 press release by the University of Cambridge:http://www.cam.ac.uk/research/news)
The consortium brings together the University of Cambridge, two other Cambridge- area academic institutes and three U.K.-based pharmaceutical companies to collectively develop precision medicines for some of the most globally devastating diseases. The consortium is pooling the specialized knowledge of academic institutions with the drug development capabilities of the pharmaceutical industry with the goal of delivering better drugs to patients.
About Astex Pharmaceuticals
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. Astex is developing a proprietary pipeline of novel therapies and has a number of partnered products being developed under collaborations with leading pharmaceutical companies. In October 2013, Astex was acquired by Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan, and operates as a wholly owned subsidiary of Otsuka from two sites with drug discovery research headquarters in Cambridge, UK and clinical development headquarters in Pleasanton, California, USA. The Otsuka Group employs approximately 43,000 people globally, and its products are available in more than 80 countries worldwide.